{
  "report_rows": [
    {
      "kpi": "Key Dermatology (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$430M vs. cons $445M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Librela & Solensia (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$144M vs. cons $143M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$2,470M vs. cons $2,504M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$1.83 vs. cons $1.858",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide midpoint ~$9.82B vs. cons $9.734B \u2014 maintained range, implicit H2 acceleration required",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide midpoint ~$6.925 vs. cons $6.879 \u2014 maintained range",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Key Derm trajectory (Qualitative)",
      "prediction": "LOWER",
      "answer": "More cautious tone on Apoquel share loss as Bafana ramps; Cytopoint held as offset",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Librela return to growth (Qualitative)",
      "prediction": "UNCHANGED",
      "answer": "Reiterated \u2014 sequential stabilization intact, back-half growth still the call",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -6.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -8.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-side estimate cuts on H2 math post-print pull FY consensus lower despite maintained guidance range; partial offset from Librela stabilization and cost program",
  "day5_confidence": "MEDIUM"
}